Palantir NHS Data Platform Unused by 29 Trusts, Guardian Reveals 2026

Palantir's NHS data platform is at the center of a growing controversy after a Guardian investigation revealed that 29 hospital trusts listed as benefiting from the £330m federated data platform (FDP) are not using all or most of its AI-powered technology. The news raises serious questions about the rollout of the flagship government AI system and the accuracy of NHS England's public claims.

According to the Guardian, the 29 trusts that NHS England publicly lists as "realising benefits" from the FDP have said the system is not live or they are not using any of its applications. One senior health official described the gap between the NHS claim and the trusts' understanding as "very misleading."

What Is the Palantir NHS Data Platform?

The federated data platform is a £330m contract awarded to US tech firm Palantir to connect scattered medical files across the NHS, speed up hospital discharges, and improve surgery scheduling. The system is intended to be a flagship government AI initiative with potentially life-saving improvements.

However, the platform has been controversial from the start due to Palantir's other contracts, including supplying AI to the Israeli military and Donald Trump's homeland security crackdown. Its billionaire founder, Peter Thiel, has also sparked concern by questioning democracy and calling technology an "incredible alternative to politics."

Why Are 29 Trusts Not Using the Platform?

The Guardian's findings suggest that many trusts are either not live on the system or are not using its applications, despite being listed as "realising benefits." This discrepancy points to potential issues with the rollout, including technical challenges, lack of training, or resistance from staff.

One senior health official called the situation "very misleading," indicating that NHS England's public statements may have overstated the platform's adoption. The gap between claims and reality could undermine trust in the NHS's handling of the contract.

The Political Fallout

The revelation comes as health secretary Yvette Cooper faces calls from MPs and campaigners to axe Palantir's contract. Critics argue that the company's involvement in controversial military and immigration projects makes it unsuitable for handling sensitive NHS data.

Palantir's UK and Europe chief executive, Louis Mosley, defended the contract, saying that ending it would be "putting politics above patients" and accused critics of "Palantir Derangement Syndrome." The company maintains that its technology can deliver significant benefits to the NHS.

What This Means for Patients and the NHS

The FDP aims to improve patient care by connecting data and enabling AI-driven insights. If the platform is not being used effectively, patients may not see the promised benefits, such as faster discharges and better surgery scheduling.

Moreover, the controversy could delay or derail the project, wasting taxpayer money and leaving the NHS without a crucial tool for modernizing its data infrastructure. The lack of transparency also raises concerns about accountability.

Key Takeaways

• 29 NHS trusts listed as benefiting from Palantir's FDP are not using all or most of its technology.
• NHS England's claims of benefits are described as "very misleading" by a senior health official.
• The £330m contract faces political pressure, with calls to axe it over Palantir's other controversial contracts.
• Palantir defends the deal, accusing critics of "putting politics above patients."
• The gap between claims and reality could undermine trust and delay patient benefits.

Comparing the Claims and Reality

What to Watch Next

The health secretary is under pressure to respond to the findings and may face questions in Parliament. Campaigners are likely to intensify calls for transparency and possibly for the contract to be terminated.

NHS England may need to clarify how it assesses benefits and whether the 29 trusts were misreported. The future of the FDP could hinge on whether Palantir can demonstrate real value and address concerns about its other activities.

As the debate continues, it's worth examining whether UK-based alternatives could provide a more acceptable solution. The Palantir alternatives for NHS: UK tech solutions might offer a way to maintain data sovereignty while improving patient care.

The controversy also highlights the importance of public trust in health data projects. The Palantir NHS data trust crisis: health minister warns of impact underscores how perceived ethical issues can jeopardize essential initiatives.

For those concerned about the implications for civil liberties, the Palantir NHS deal: why UK values are at risk with surveillance tech provides a deeper analysis of the potential risks.

Legal challenges are also mounting, with the Palantir NHS data platform facing 44,000 legal objections, which could further complicate the rollout.

Beyond the NHS, Palantir's involvement in military AI raises similar control questions, as discussed in Palantir Maven: Europe's military AI and the control question.

Finally, the rejection of Palantir's patient data tech by many NHS trusts in England, as reported in Palantir patient data tech rejected by many NHS trusts in England, suggests that resistance is widespread and may be growing.